title: Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
abstract: In recent years, significant progress has been made in the use of monoclonal antibodies in the treatment of systemic lupus erythematosus (SLE). Advances in our understanding of the complexity of SLE immunopathogenesis have led to the testing of several biologic agents in clinical trials. Monoclonal therapies currently emerging or under development include B-cell depletion therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and anticytokine therapies. Issues remain, however, regarding clinical trial design and outcome measures in SLE which need to be addressed to optimize translation of these promising therapies into clinical practice.
authors: Louise Coote Lupus Unit St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
authors: Natasha
authors: N
authors: Jordan
authors: Pamela Mk
authors: PM
authors: Lutalo
authors: David P
authors: DP
authors: D'Cruz
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D001691:Biological Therapy / Q000639:trends*; D002470:Cell Survival / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D008212:Lymphocyte Depletion; D020239:Receptor Cross-Talk / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D057170:Translational Research, Biomedical; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D016898:Interferon-alpha; C505719:TNFSF13B protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; C511911:belimumab
keywords: APRIL; B-cell depletion; BAFF; IFN-α; belimumab; lupus nephritis; systemic lupus erythematosus